DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis (EDS), making this technology accessible to labs with the world’s first benchtop enzymatic synthesis instrument, SYNTAX (TM). By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Website
www.dnascript.com
Related News
DNA Script expands leadership team with appointment of Madoo Varma as Vice President of Business Development
5 Sofinnova Partners portfolio companies selected to French Tech 120
Sofinnova Partners congratulates portfolio company DNA Script for the success of its €142M ($165M) Oversubscribed Series C Fundraise
DNA Script Expands Series B to $89M
Sofinnova Partners’ DNA Script Raises $38.5 Million in Series B Financing
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.